AnaptysBio (NASDAQ:ANAB) Director Sells $193,362.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director J. Anthony Ware sold 3,900 shares of AnaptysBio stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $49.58, for a total value of $193,362.00. Following the completion of the transaction, the director owned 9,630 shares of the company’s stock, valued at approximately $477,455.40. This represents a 28.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

AnaptysBio Trading Down 0.0%

Shares of ANAB stock opened at $50.03 on Friday. The company has a market capitalization of $1.39 billion, a P/E ratio of -17.74 and a beta of 0.29. The business’s 50 day moving average is $40.14 and its two-hundred day moving average is $29.69. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $51.43.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, research analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has approved a stock repurchase program on Friday, November 21st that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC boosted its holdings in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the last quarter. Rhumbline Advisers lifted its position in AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after buying an additional 826 shares in the last quarter. Bessemer Group Inc. boosted its stake in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,292 shares during the last quarter. Corton Capital Inc. grew its holdings in AnaptysBio by 12.2% in the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 1,305 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Wells Fargo & Company lifted their price objective on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. HC Wainwright cut their price objective on AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Monday, November 24th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Finally, Stifel Nicolaus lowered their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.40.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.